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Abstract
Prostate specific antigen (PSA) testing of asymptomatic men enables the diagnosis of localised prostate cancer which is potentially 
curable, but it also poses certain risks. Doctors run the risk of litigation for failure to diagnose cancer at a curable stage, while 
patients run the risk of being diagnosed with non-significant cancer, incurring costs and possible complications without any survival 
benefit. 
PSA reflects a ‘range of risk’ for prostate cancer: the higher the PSA, the greater the risk. There is no ‘normal’ PSA, because even 
with a PSA below 4 ng/ml cancer can be detected on biopsy in up to 20% of men. However, the prevalence of high-grade (life-
threatening) cancer is relatively low at low PSA values. 
The following recommendations appear reasonable: 
•  PSA testing should be offered to all men aged 50 years or more (45 years in those with a family history of prostate cancer and 
– possibly – African men); 
•  Alternatively, PSA testing should be done at 40, 45 and 50 years and then every two to four years (the lower the baseline value, 
the lower the risk of ever developing prostate cancer);  
• PSA testing should be repeated annually if it is more than 2 ng/ml and every two years if less than 2 ng/ml;
•  Stop PSA testing in asymptomatic men over 75 years or with less than 10 years’ life expectancy, and in those aged over 65 
years with PSA less than 0.5 to 1 ng/ml. 
The free-to-total PSA ratio and PSA density (PSA divided by prostate volume) can be used to decide which patients need prostatic 
biopsy. PSA velocity (increase of PSA per year) can predict which men are likely to develop prostate cancer or to die of it (the higher 
the PSA velocity, the greater the risk). PSA doubling time (the period it takes for the PSA to double) correlates with the prognosis 
both before and after treatment (the shorter the doubling time, the worse the prognosis). 
An internet Prostate Cancer Risk Calculator is available which calculates a man’s risk by taking into account his age, race, family 
history, PSA level, findings on rectal examination and prior negative biopsy. Although this is a very convenient tool, it should be 
used with caution, especially at low PSA values, because there is a real risk of overdiagnosis. 
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(2):19-24
Introduction 
The use of prostate specific antigen (PSA) in the diagnosis of prostate 
cancer remains a topic of considerable controversy. It is especially 
problematic for busy family practitioners who do not have the time to 
peruse the vast literature on this topic.1,2 Currently, entering the words 
“prostate specific antigen” into an electronic literature index such as 
Pubmed produces more than 15 000 articles. The aim of this review 
is to provide the general practitioner with a brief but comprehensive 
update on the use of PSA testing in clinical practice. 
What is PSA? 
Prostate specific antigen (PSA) is an enzyme, a serine protease 
(molecular weight 33 kilodalton) that is produced almost exclusively 
by the prostatic epithelial cells. It is secreted into the prostatic ducts 
and forms part of the seminal fluid. Its function is possibly to lyse the 
semen coagulate formed a few minutes after ejaculation, although 
the physiological role of clotting and lysing of the ejaculate remains 
unknown.  
Why all the fuss about PSA? 
The protein now known as PSA was first identified in seminal plasma 
in 1966 and was given the name gamma-seminoprotein. It proved 
useful as a forensic marker in rape cases.2 PSA was biochemically 
characterised in seminal fluid and a serum assay was developed 
in 1979.3,4 During the 1980s it was realised that serum PSA levels 
correlate with the tumour burden in men with prostate cancer. Its 
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clinical use gained rapid momentum worldwide during the 1990s and 
it has become the most clinically useful of all serum tumour markers. It 
has a higher specificity for prostate cancer than the mammogram does 
for breast cancer, so it is somewhat ironic that its use should remain 
controversial.5 
PSA testing of asymptomatic men has enabled the diagnosis of 
localised or early-stage prostate cancer. The widespread clinical 
use of PSA has led to a dramatic ‘stage migration’ in the USA and 
Europe – whereas previously about 80% of men were diagnosed with 
advanced prostate cancer (incurable), nowadays more than 80% are 
diagnosed with localised cancer (potentially curable). However, the 
availability of PSA testing has created new risks for both doctor and 
patient. There have been several cases of litigation where practitioners 
were sued for millions because of failure to diagnose prostate cancer 
at a curable stage. For patients there is the risk of overdiagnosis and 
overtreatment of non-significant prostate cancer, incurring costs and 
possible complications of treatment without any significant benefit.   
What determines serum PSA levels? 
PSA is secreted into the prostatic ducts and very little PSA enters 
the bloodstream, so its concentration is about a million times higher 
in seminal fluid than in serum. Elevated serum PSA results from 
disruption of the cellular architecture within the prostate gland, with 
loss of the normal barrier formed by the basal layer and basement 
membranes, so that PSA ‘leaks’ into the circulation. 
Conditions that increase serum PSA: 
• Prostate cancer 
• Benign prostatic hyperplasia (BPH)
• Prostatitis 
• Acute urinary retention (AUR) 
• Prostatic biopsy, transurethral resection of the prostate (TURP)
• Digital rectal examination (DRE) 
• Ejaculation
Prostate cancer cells usually make less rather than more PSA 
compared with normal prostate cells, so the elevated PSA associated 
with prostate cancer is due to more ‘leakage’ of PSA into the 
bloodstream rather than to increased production. In general there is a 
good correlation between PSA and cancer volume, i.e. the higher the 
PSA the larger the cancer. However, the correlation is not absolute and 
there are exceptions to the rule, i.e. high PSA with a small cancer, or 
metastatic cancer with a low PSA.  
PSA increases with age and with increasing prostate volume, mainly 
due to BPH, which becomes more prevalent with age. AUR is often 
precipitated by urinary tract infection (UTI), prostatitis or prostatic 
infarction, which can all cause an elevated PSA. Catheterisation or 
cystoscopy in a normal man does not cause a clinically significant PSA 
elevation. Catheterisation in someone with AUR is often associated 
with an elevated PSA, most probably because of underlying UTI, 
prostatitis or infarction that precipitated the AUR. DRE may increase 
the PSA, but usually within the laboratory error of the assay, so it is not 
clinically significant. Nonetheless, it is preferable to draw blood for PSA 
before doing a DRE. 
Ejaculation may cause a statistically (but not clinically) significant PSA 
elevation. 
The half-life of serum PSA is two to three days. Prostatic trauma, 
e.g. biopsy or TURP, will dramatically elevate the PSA, which takes 
about four weeks to return to baseline. Therefore it is very important 
not to repeat PSA testing within four to six weeks after any event 
that is known to elevate the PSA, otherwise a false high value will be 
obtained. 
Factors that decrease serum PSA: 
• Decreased serum testosterone (hypogonadism)
• Androgen deprivation therapy (ADT) 
• Finasteride and dutasteride 
Low serum testosterone is associated with a relatively low PSA. The 
risk of finding prostate cancer on biopsy at any given PSA is higher in 
men with a low serum testosterone (hypogonadism) than in men with a 
normal testosterone.6,7  
ADT, whether surgical (bilateral orchidectomy) or medical (oestrogens, 
luteinising hormone-releasing hormone agonists, anti-androgens) will 
almost always cause a dramatic decrease in PSA.   
Finasteride and dutasteride are 5-alpha-reductase inhibitors (5ARI) 
used in the treatment of BPH. They inhibit the action of 5-alpha-
reductase which converts testosterone to dihydrotestosterone (DHT). 
They reduce the PSA level by about 50% after six to 12 months of 
treatment. In patients on 5ARI treatment a PSA increase of more 
than 0.3 ng/ml over the nadir (lowest) value should raise suspicion of 
prostate cancer.8 
What is a normal PSA? 
Initial studies suggested that a PSA of 4.0 ng/ml indicates a high risk 
of prostate cancer and should be used as a threshold value (cut-off) 
for recommending a prostate biopsy. Later studies suggested that a 
cut-off value of 3.0 ng/ml or even 2.5 ng/ml should be used. However, 
it is now recognised that PSA reflects a continuous ‘range of risk’ for 
prostate cancer, rather than normal or abnormal values.
The Prostate Cancer Prevention Trial, which evaluated finasteride 
for the prevention of prostate cancer, provided information about the 
prevalence of prostate cancer in several thousand men with PSA below 
3 ng/ml who underwent biopsy.9 Other studies have investigated the 
risk of finding cancer in men with high PSA values (Table I).10 
















* Cancer yield is the total number of cancers detected divided by the total 
number of men undergoing biopsy with a PSA in the given range.9,10    
The relatively high cancer yield on biopsy in men with low PSA levels 
is not really surprising, because it has long been known that there is a 
high prevalence of prostate cancer that can be detected histologically 
in young men aged 30 to 50 years who died as a result of trauma.11 
However, the proportion of high-grade cancer is relatively low, ranging 
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from about one in ten cases diagnosed with a PSA below 1 ng/ml to 
one in four cases at a PSA of 2–4 ng/ml to approximately one in three 
cases with a PSA of 4–10 ng/ml (Table I). 
The problem in choosing a single PSA cut-off for recommending 
biopsy is that there is an inverse relationship between sensitivity and 
specificity, and it is difficult to decide where the balance should be. 
The higher the PSA cut-off that is chosen, the more specific it is 
(because the higher the PSA, the more likely that prostate cancer 
is present, so few unnecessary biopsies will be done) but the less 
sensitive it is (because it will miss many cancers which are present with 
a PSA below the high cut-off). 
The lower the PSA cut-off that is chosen, the more sensitive it is (it 
will detect almost all cancers, including those which are present with 
a low PSA) but the less specific it is (many more biopsies will be done 
unnecessarily in men with a low PSA who do not have cancer). For 
example, using a PSA threshold of 4.0 ng/ml, about 25% of prostate 
cancers are not detected (false-negative rate) whereas about 65% of 
biopsies will not show cancer (false-positive rate).8 
Another problem is that lowering the PSA threshold, e.g. from 4 ng/ml 
to 2.5 ng/ml, would double the number of men requiring biopsy. Many 
of these men harbour low-grade, small-volume cancers that will not 
cause the patient’s death, so there is a high risk of overdiagnosis and 
overtreatment.12
How reproducible are PSA assays? 
Serum levels of PSA are very low, so the assay has to measure a tiny 
quantity of protein – in nanogram per millilitre or microgram per litre 
– and the risk for laboratory error is larger than with assays measuring 
proteins at higher concentrations. There is normal physiological 
variation. Also, there are different types of PSA assays which may give 
slightly different results on the same specimen. Variation in PSA assay 
results can be as high as 20 to 40%.13  
It is very important to use the same laboratory and the same assay 
when doing sequential PSA tests in the same person. It is also 
important not to base a major clinical decision on a minor change in 
PSA, unless it has been confirmed with a repeat test.  
What are age- and race-specific PSA ranges? 
PSA increases with age, mainly due to the development of BPH. This 
means that, for any given PSA value, the chance of finding cancer on 
biopsy is higher in younger than in older men. 
It is more important to diagnose early-stage prostate cancer in a 
younger than in an older man, because the cancer is more likely to be 
the cause of death in the younger man, whereas the older man may 
die of some other condition. A lower PSA cut-off value in younger men 
will reduce the risk of underdiagnosis (missing prostate cancer) and a 
higher PSA cut-off in older men will reduce the risk of overdiagnosis 
(finding cancer which is unlikely to cause death).14,15  
Studies from the USA have indicated that prostate cancer may occur 
at a younger age in African-American men and that PSA at diagnosis 
in black men is higher than in white men. Therefore it has been 
suggested that a younger age and lower PSA cut-off value should be 
used as indication for prostate biopsy in black men. However, there is 
a lack of studies to show whether this also applies to black men living 
in Africa.16  
Who should be offered PSA testing? 
Prostate cancer is rarely diagnosed in men younger than 50 years, 
accounting for less than 0.1% of all patients. About 85% of cases 
are diagnosed after the age of 65 years. It is usually recommended 
that PSA testing be offered from the age of 50 onwards, and perhaps 
earlier (age 45) for those at higher risk (family history of prostate 
cancer, black African race).9  
It has also been recommended that all men be offered baseline PSA 
testing at age 40 years and that the frequency of follow-up testing 
should depend on this baseline level. The relative risk of developing 
prostate cancer during the next 10 years is strongly correlated to the 
baseline PSA.17 
The recommended upper age limit for PSA screening varies from 70 to 
75 years. It is generally accepted that PSA screening of asymptomatic 
men should be limited to those with a life expectancy of more than 10 
years. This is because early stage prostate cancer is unlikely to cause 
the patient’s death in less than 10 years. It has been shown that if PSA 
testing were discontinued in men aged 65 years with PSA levels below 
1 ng/ml, it is unlikely that a prostate cancer would be missed later in 
life.18  
How often should PSA testing be repeated? 
Long rescreening intervals may miss detecting curable cancer in those 
with fast-growing cancers, and short intervals may lead to unnecessary 
testing, overdiagnosis and overtreatment of those with slowly growing 
cancers. The problem is to define a screening interval that will minimise 
the risks of both underdiagnosis and overdiagnosis. 
It has been recommended that all men older than 50 should have 
annual PSA screening regardless of risk. Some authors have 
suggested biennial screening (once every two years) for men with PSA 
levels of 2 ng/ml or less and annual screening for those with PSA levels 
of 2 ng/ml or above. It has also been suggested that men with PSA 
levels of less than 1 ng/ml can safely be scheduled for a three-year 
testing interval. The large European screening study has shown that a 
rescreening interval of four years may be reasonable.19–22   
However, it has also been suggested that a two- or four-year PSA 
screening interval in men with initial serum PSA less than 2 ng/ml 
would result in substantial delays in prostate cancer detection, although 
the extent to which these delays would affect treatment outcomes 
remains undetermined.23
In summary, the following recommendations appear reasonable: 
• PSA testing should be offered to all men aged 50 years or more 
(45 years in those with a family history of prostate cancer and 
– possibly – African men); 
• Alternatively, PSA testing should be done at 40, 45 and 50 years 
and then every two to four years, depending on the baseline PSA 
value;  
• PSA testing should be repeated annually if PSA is more than 2 
ng/ml and every two years if it is less than 2 ng/ml;
• Stop PSA testing in asymptomatic men over 75 years or with less 
than 10 years’ life expectancy, and in those aged over 65 years 
with PSA less than 0.5 to 1 ng/ml.
In men with a diagnosis of prostate cancer, whether treated or not, it 
is virtually never necessary to repeat the PSA at intervals of less than 
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three to six months, because PSA changes over shorter intervals are 
very unlikely to have major implications. 
Can PSA replace digital rectal examination (DRE)? 
In a man with lower urinary tract symptoms (LUTS), haematuria or 
other symptoms that may indicate advanced prostate cancer (back 
pain, weight loss, anaemia), a DRE is essential. The question is 
whether DRE should be performed in all asymptomatic men aged 50 to 
70 years, because the majority who have prostate cancer do not have 
a palpable abnormality. 
Most screening studies have shown that prostate cancer detection 
rates are significantly higher using PSA alone than using DRE alone, 
but is highest when a combination of the two is used. An abnormal 
DRE has been shown on multivariate analysis to be a predictor of 
high-grade (life-threatening) prostate cancer, independent of PSA.24 
However, the large European screening study has shown no additional 
benefit in using DRE or transrectal ultrasound (TRUS) rather than PSA 
alone.25 
Nonetheless, examination of the external genitalia and DRE should 
continue to form part of a thorough clinical examination in all men 
with symptoms, and in asymptomatic men aged 50 to 70 years, just 
as dipsticks urinalysis should form part of the clinical examination, 
because in some patients (albeit a small minority) an unexpected but 
important abnormality may be detected.   
Who should have a prostate biopsy? 
An internet Prostate Cancer Risk Calculator is available on the 
National Cancer Institute website. (It can be found by simply typing 
“prostate cancer risk calculator” into a search engine such as Google). 
The complete address is: http://www.compass.fhcrc.org/edrnnci/bin/
calculator/main.asp?t=prostate&sub=s1&m=&v=prostate&x=Prostate
%20Cancer 
This computer programme uses data from large PSA-based cancer 
detection studies to calculate a man’s risk of having cancer diagnosed 
on prostate biopsy by taking into account his age, race, family history 
of prostate cancer, PSA level, DRE result and whether he had a prior 
negative biopsy. 
A representative sample of risk estimates for a 60-year-old white man 
with no prior prostate biopsy is shown in Table II. It can be seen that 
the risk increases with increasing PSA, and at each level of PSA the 
risk is higher if there is a family history of prostate cancer and if the 
DRE is abnormal.
It should be noted that the risk of finding high-grade (i.e. life-
threatening) cancer is much lower than the risk of finding any 
cancer, especially with a PSA of 1–4 ng/ml, where high-grade cancer 
constitutes only one in 14 to one in five of cases, whereas with a PSA 
of 20 ng/ml about half of cases will be high-grade cancer (Table II). 
Therefore, the computerised risk calculator should be used with 
caution, especially at low PSA values, because there is a real risk 
of overdiagnosis and overtreatment. It is estimated that lowering 
the PSA cut-off value for biopsy to levels below 4 ng/ml may lead 
to overdiagnosis rates of 30 to 50%, with a huge impact on costs 
of treatment and morbidity due to complications and side effects of 
treatment.26–29  
How is a prostate biopsy done? 
Prostate biopsy is usually done under TRUS guidance with an 
18-gauge needle inserted through the rectum or (less commonly) 
the perineum. It can be done under general anaesthesia, but local 
anaesthesia is usually sufficient. Prophylactic antibiotic treatment is 
essential to prevent bacteraemia. Complications of prostate biopsy 
include pain or discomfort, bacteraemia or septicaemia, urinary tract 
infection, prostatitis, haematuria, haematospermia, rectal bleeding and 
acute retention.
Traditionally six biopsy cores were taken, three on each side (“sextant” 
biopsy). Subsequent studies showed that taking more cores produced 
a higher rate of positive biopsies (“the more holes you drill, the more 
oil you find”) and currently there is controversy as to whether eight, 10, 
12 or 18 cores should be taken. There are even centres advocating 
“saturation biopsy” where an average of 24 (and up to 45) cores are 
taken.30 It has also been recommended that the number of cores 
should be determined by the size of the prostate and the age of the 
patient (more cores taken in larger prostates and in younger men).31 
However, it should be kept in mind that increasing the number 
of biopsy cores increases the risk of diagnosing small-volume 
cancers which may not require treatment, i.e. it increases the risk of 
overdiagnosis and overtreatment. 
Is informed consent necessary for PSA testing? 
PSA testing in asymptomatic men may have far-reaching 
consequences in terms of the costs and complications of treating 
prostate cancer, without guaranteed benefits in terms of improved 
quality of life or longer survival. On the other hand, failure to diagnose 
prostate cancer at a curable stage may have serious medico-legal 
repercussions. Therefore it is important for practitioners to discuss the 
option of PSA testing with all asymptomatic men over the age of 45 to 
50, and up to the age of 75 years, provided they have a life expectancy 
of 10 years. 







PSA ng/ml Cancer (%) High-grade cancer (%) Cancer (%) Cancer (%)
1 14 1 18 35
2 23 3 28 49
3 30 5 36 58
4 35 7 41 64
5 39 9 46 68
10 54 19 61 75
20 68 37 73 75
Table II:  Risk of finding prostate cancer on biopsy in a 60-year-old white man 
with no prior prostate biopsy* 
* According to the Prostate Cancer Risk Calculator which can be accessed on 
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The patient should be given the following basic information: 
• Prostate cancer is one of the most common types of cancer in men.
•  The risk is higher with age, and when there is a family history of 
prostate cancer (father, brothers, uncles). 
•  It can be diagnosed at an early stage with the aid of DRE and PSA 
testing. 
• If diagnosed early, it can be cured.
•  However, there are costs and risks involved in the diagnosis and 
treatment. 
•  The potential benefit of early diagnosis is that later suffering and 
death due to prostate cancer may be avoided. 
•  However, there may be a loss in quality of life without guaranteed 
benefit of longer survival. 
If the patient declines the offer of PSA testing, it should be recorded in 
the clinical notes. 
Should there be state-funded PSA screening? 
There are several reasons why screening for prostate cancer makes 
good sense. It has a high prevalence, there is no effective prevention, 
it does not cause symptoms before it is advanced and incurable, it 
causes significant morbidity and mortality, there is a screening test 
which is more sensitive and specific in detecting early cancer than 
most screening tests for other cancers, a definitive diagnosis can 
be made relatively easily and reliably, and there is effective curative 
treatment. 
The problems are that prostate cancer occurs in elderly men with 
competing causes of mortality, not all prostate cancers are life-
threatening, its natural course is prolonged (even if untreated), so that 
the potential benefit of curative treatment must be weighed against the 
costs and complications of potentially unnecessary treatment in men 
who will die of some cause other than prostate cancer.5 In short, the 
potential gain (living longer) has to be weighed up against the potential 
pain (losing quality of life).    
Whether the term screening or early detection is used, PSA has 
already made a significant impact on prostate cancer. In the USA, the 
percentage of men with metastatic cancer at diagnosis has steadily 
decreased since 1991 and organ-confined disease found at radical 
prostatectomy has increased from less than 50% to more than 70% 
(stage migration). A decline in prostate cancer mortality is beginning 
to become evident in the USA and elsewhere, but it is not yet clear 
whether this is the effect of curative treatment or due to other factors.  
Two large-scale randomised trials of PSA screening for prostate cancer 
in men aged 50 to 74 years are currently under way: the Prostate, 
Lung, Colorectal and Ovary Cancer trial in the USA, and the European 
Randomised Study of Screening for Prostate Cancer. The PLCO and 
ERSPC trials are designed to establish whether PSA screening will 
decrease prostate cancer specific mortality, but it will take several 
years before the final results of these studies are known.2 
Widespread PSA screening should not be implemented before there is 
proof that it does more good than harm. However, it is strongly advised 
that doctors should give their patients information about the potential 
risks and benefits of early detection and treatment of prostate cancer, 
and assist them in making informed decisions about testing.5 
What is the free/total PSA ratio (f/t PSA)? 
PSA in the serum may be bound (complexed) to three different 
proteins. The bound PSA is enzymatically inactive but remains 
immunoreactive and can therefore be measured by immuno-assay. 
Men with prostate cancer have a greater fraction of total PSA bound to 
serum proteins and a lower percentage that is free compared with men 
who do not have prostate cancer. 
The free and total PSA values can be measured separately and 
expressed as a free to total PSA (f/t PSA) ratio or as the percentage 
free PSA. The lower the f/t ratio, the higher the risk of prostate cancer. 
There is some controversy, but if the f/t PSA ratio is below 0.15 (free 
PSA below 15%) the risk of prostate cancer is considered sufficiently 
high to warrant biopsy or re-biopsy (if there is a previous negative 
biopsy).32 Some authors recommend that a biopsy should be done in 
everyone with a percentage free PSA lower than 23%.  
The f/t PSA ratio is only useful in men with a PSA less than 10 ng/ml 
in whom there is uncertainty as to whether a biopsy should be done or 
repeated. If the PSA is over 10 ng/ml the risk of prostate cancer is so 
high that a biopsy should be recommended, and repeated if the first 
biopsy is negative. There is no reason to do f/t PSA in all men, or in 
those with a total PSA over 10 ng/ml.   
What is complexed PSA (cPSA)? 
There is an assay that measures only the complexed forms of PSA 
bound to serum proteins; therefore cPSA gives the total minus free 
PSA in one assay. It provides the same information as the f/t PSA ratio, 
and its clinical usefulness is in better selecting which men should have 
a prostate biopsy.33 
However, just as f/t PSA should not be routinely done, because it has 
no clinical relevance in the majority of men with a PSA outside the 
4–10 ng/ml range, the routine use of cPSA is questionable. In the vast 
majority of cases it is of no importance what the free versus bound 
fractions of PSA are (the PSA is either too low to warrant biopsy, or it is 
so high that biopsy is mandatory). 
What is PSA density (PSAD)? 
PSA density (PSAD) is the serum PSA divided by the prostate volume 
as measured by TRUS. Any given volume of prostate cancer will 
elevate serum PSA about 10 times more than the same volume of 
BPH, i.e. the ‘leakage’ of PSA into the serum is 10 times higher with 
any volume of cancer than with the same volume of BPH. 
The higher the PSAD, the greater the risk of prostate cancer, and the 
lower the PSAD, the lower the risk of cancer. In men with a normal 
DRE and PSA between 4 and 10 ng/ml, a PSAD greater than 0.15 
indicates a higher risk of prostate cancer, so a biopsy should be 
advised or, if there is a prior negative biopsy, re-biopsy should be 
recommended.34  
What is PSA velocity (PSAV)? 
PSA velocity (PSAV) is the increase of PSA per year. This is calculated 
by using three or more PSA values taken over 18 months or more. 
It has been shown that a PSAV of greater than 0.75 ng/ml/year 
indicates a very high risk of developing prostate cancer more than 
five years later.35, 36 Subsequent studies have suggested that a PSAV 
of greater than 0.5 ng/ml/year indicates an increased risk of prostate 
cancer. PSAV can also predict the response to treatment and the 
cancer-specific survival.36–38 
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What is PSA doubling time (PSADT)? 
PSA doubling time (PSADT) is the time that it takes for the serum PSA 
to double in value. The pre-treatment PSADT predicts the outcome 
after radical prostatectomy as well as radiotherapy – the shorter the 
PSADT, the worse the prognosis. With PSA recurrence after treatment, 
the shorter the PSADT, the shorter the patient’s survival. In general, a 
PSADT less than six to 12 months denotes a poor prognosis, whereas 
a PSADT of 18 to 24 months or more indicates a good prognosis.39–42  
What is meant by PSA kinetics? 
It is now well recognised that the changes in PSA values over time 
(PSA kinetics) are much more valuable than single PSA values.43 
PSAV is usually calculated by simple linear regression, and PSADT is 
calculated by log linear regression using all available PSA values.42,44 
PSAV and PSADT can be easily determined by using a calculator 
such as that available on the website of the Memorial Sloan Kettering 
Cancer Centre (MSKCC) at http://www.mskcc.org/. 
How useful is PSA testing?
The greatest clinical value of PSA is in predicting and following the 
response to treatment of patients with prostate cancer.28 The higher the 
pre-treatment PSA, the worse the prognosis, regardless of therapy.45 
After radical prostatectomy an increasing PSA is an early indicator of 
treatment failure. The time to PSA recurrence (biochemical failure) 
after radical prostatectomy is an important prognosticator – the shorter 
the time to PSA recurrence, the shorter the survival. 
The PSA nadir (lowest level) as well as the time to PSA increase after 
radiotherapy are important prognosticators – the higher the nadir and 
the shorter the time to PSA increase, the worse the prognosis.45 With 
androgen-deprivation therapy the prognosis correlates with the PSA 
nadir (lower nadir indicates longer survival), the time to reach PSA 
nadir (shorter time equals longer survival) and the time to PSA increase 
(shorter interval indicates poorer prognosis).  
Although PSA generally correlates well with prognosis, an increasing 
PSA does not mean that the patient will die when the PSA has reached 
a certain level. Laboratory assays have an upper limit, and measuring 
PSA levels above this limit requires serial dilution of the specimen, 
therefore laboratories sometimes only report the PSA as ‘more than 
100 ng/ml’ when it exceeds the detection limit. However, with serial 
dilution very high PSA levels can be measured – the highest in this 
author’s experience is a reported value of 157 000 ng/ml (almost 
40 000 times more than the traditional ‘normal’ value of 4 ng/ml). 
Therefore, patients can be reassured that PSA is of secondary 
importance compared with symptoms, so that they do not become 
obsessively anxious about a rising PSA and do not insist on repeated 
testing at intervals less than six to three months. As long as the patient 
is symptom-free and feels well, he should forget about his PSA and let 
his doctor worry about it.  
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